February 7, 2011

Pantec Biosolutions reports first successful IVF pregnancy using P.L.E.A.S.E.® -FSH patch

 

Pantec Biosolutions AG announced today that a woman has successfully conceived after being implanted with a fertilized oocyte. The oocyte (egg cell) donor was treated with the company’s FSH (follicle stimulating hormone) patch subsequent to skin microporation with Pantec’s proprietary P.L.E.A.S.E.® (Precise Laser Epidermal System) device. The CEO of Pantec Biosolutions, Dr. Christof Boehler, announced this news during a scientific presentation at the 16th Annual Drug Delivery Partnerships 2011 conference in Miami, Florida, USA. The pregnancy is the first to occur from a previously announced study in which follicular maturation was achieved using P.L.E.A.S.E.® microporation and the FSH (IVF002) patch. Following the oocyte donation, the fertilized egg was transferred to the recipient, who subsequently became pregnant. The trial team was led by principal investigator, Dr. Petr Uher and medical expert, Professor Herbert Zech. The presentation can be downloaded below. “We are very pleased that our treatment has helped a patient conceive and we wish her the best during her pregnancy,” said Christof Boehler, CEO of Pantec Biosolutions. “This is an extremely important milestone; not only for our company, but also for all women undergoing IVF treatments - it is a big step towards making the tedious IVF procedure more comfortable for all those hoping to get pregnant.”

About Pantec Biosolutions and P.L.E.A.S.E.®

Pantec Biosolutions AG is a private drug delivery company specialised in using laser microporation technology to deliver large molecular weight drugs into the epidermis for local or systemic uptake. Its proprietary P.L.E.A.S.E.® (Precise Laser Epidermal System) platform enables efficient, needle-free and painless administration of biopharmaceutical drugs, in varying and individualised dosages, through partnered patch technology. The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of US$1.5 – 2 billion.

Pantec Biosolutions’ P.L.E.A.S.E.® platform is available both for the development of the Company’s own pipeline and for penetration into new markets through strategic partnerships. Pantec Biosolutions is based in Ruggell, Liechtenstein.
 

Dr. Christof Boehler
CEO
Pantec Biosolutions AG
t:  +423 377 7800
e: info(at)pantec-biosolutions.com   
Dr. Robert Mayer
Senior Account Manager
College Hill Life Sciences
t:  +49 (0)89 52 38 80 30
e: robert.mayer(at)collegehill.com
Download DDP Presentation

DDP 2011 Presentation